SCHEMBL21991735

SCHEMBL21991735

CCCCC(Oc1ccc(C(F)(F)F)cc1)C(=O)OCC

nearest known ligand 0.48

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
PPARG P37231 4/20 0.48
PPARA Q07869 3/20 0.48
ALDH2 P05091 2/20 0.46
POLB P06746 1/20 0.43
IDH1 O75874 1/20 0.41
NPSR1 Q6W5P4 1/20 0.41
SLC6A9 P48067 5/20 0.41
EPHX2 P34913 1/20 0.40
CYP1A1 P04798 1/20 0.39
CYP1B1 Q16678 1/20 0.39
MAOB P27338 1/20 0.39
MEN1 O00255 1/20 0.39
KMT2A Q03164 1/20 0.39
PTGES O14684 1/20 0.39
ALOX5 P09917 1/20 0.39
PTPN1 P18031 1/20 0.39
PPARD Q03181 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21991252 0.96 PPARG (0.45) PPARGPPARAALDH2POLBIDH1
SCHEMBL21991793 0.91 MAOB (0.53) PPARGMAOBALOX5
SCHEMBL21991229 0.89 PPARG (0.48) PPARGPPARASLC6A9MEN1KMT2A
SCHEMBL21991237 0.87 PPARG (0.46) PPARGPPARAPOLBNPSR1SLC6A9
SCHEMBL21991773 0.86 PPARG (0.60) PPARGPPARAALDH2SLC6A9PTGES
SCHEMBL11361509 0.86 PPARG (0.52) PPARGPPARAPOLBIDH1NPSR1
SCHEMBL21991250 0.86 PPARG (0.45) PPARGPPARASLC6A9EPHX2MEN1
SCHEMBL21991234 0.85 ALDH2 (0.48) PPARGPPARAALDH2NPSR1MEN1
SCHEMBL21991479 0.84 PPARG (0.43) PPARGPPARASLC6A9MEN1KMT2A
SCHEMBL4942052 0.83 PPARG (0.45) PPARGPPARAPOLBIDH1NPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220409566-A1 CCL5 Inhibitors LAPKO INC, dba AFECTA PHARMACEUTICALS 2022-12-29 US disclosed
US-11318111-B2 CCL5 inhibitors LAPKO INC (US) 2022-05-03 US disclosed
US-20210196665-A1 CCL5 Inhibitors AFECTA PHARMACEUTICALS, INC. (US) 2021-07-01 US disclosed
US-10940132-B2 CCL5 inhibitors AFECTA PHARMACEUTICALS, INC. (US) 2021-03-09 US disclosed
US-20200138766-A1 CCL5 INHIBITORS LAPKO INC. DBA AFECTA PHARMACEUTICALS 2020-05-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200138766-A1 CCL5 INHIBITORS CCL5, CCL11, CCR5 PPARG 1583/4885PPARA 806/4885ALDH2 1675/4885
US-20210196665-A1 CCL5 Inhibitors CCL5, CCL11, CCR5 PPARG 1583/4885PPARA 806/4885ALDH2 1675/4885
US-10940132-B2 CCL5 inhibitors CCL5, CCL11, CCR5 PPARG 1583/4885PPARA 806/4885ALDH2 1675/4885
US-11318111-B2 CCL5 inhibitors CCL5, CCL11, CCR5 PPARG 1583/4885PPARA 806/4885ALDH2 1675/4885
US-20220409566-A1 CCL5 Inhibitors CCL5, CCL11, CCR5 PPARG 1583/4885PPARA 806/4885ALDH2 1675/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.